Drug Development

Abbott laboratories says U.S. FDA approves tecnis symfony intraocular lenses

15th July 2016

- Approval includes toric version of symfony iol for people with astigmatism- lenses provide high-quality continuous vision so patients can...

Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines

by Yuvraj_pawp

14th July 2016

• Collaboration aims to develop PROteolysis TArgeting Chimeric molecules (PROTACs) – a new therapeutic modality that is able to degrade...

Health Canada approves Abbott’s Absorb Bioresorbable Stent

by Yuvraj_pawp

14th July 2016

Abbott announced that Health Canada has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available...

Lilly And Boehringer Ingelheim Announce Clinical Trial Collaboration In Metastatic Breast Cancer

by Yuvraj_pawp

13th July 2016

Eli Lilly and Company and Boehringer Ingelheim announced a new collaboration on a Phase 1b study that will evaluate the...

Sandoz Biosimilar Etanercept Recommended By Fda For Approval To Treat Multiple Inflammatory Diseases

by Yuvraj_pawp

13th July 2016

Sandoz, a Novartis division and leader in biosimilars, announced today that the US FDA Advisory Committee recommended approval of its...

U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets

by Yuvraj_pawp

13th July 2016

Janssen Pharmaceuticals, Inc one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced today that the U.S. Food...

Bayer and X-Chem Expand Drug Discovery Collaboration to Discover Novel Medicines

by Yuvraj_pawp

12th July 2016

Bayer and X-Chem, Inc focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics,...

AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT

by Yuvraj_pawp

11th July 2016

AbbVie a global biopharmaceutical company, announced that the U.S. FDA granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody...

EC Grants Marketing Authorization for Gilead’s Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C

by Yuvraj_pawp

8th July 2016

Gilead Sciences, Inc announced that the European Commission has granted marketing authorization for Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the...